The Role Of Real World Evidence To Support US FDA And TGA Registrations
Source: Novotech
Real world evidence (RWE) can contribute valuable information to new medicine registrations, in particular for diseases that are difficult to assess in randomized clinical trials (RCTs) and for emerging technologies such as gene and cell therapies to help enhance our understanding of such products.
Regulatory agencies worldwide are considering how they may incorporate RWE into their decision making processes for new medicine applications.
access the Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
Subscribe to Cell & Gene
X
Subscribe to Cell & Gene
Novotech
This website uses cookies to ensure you get the best experience on our website. Learn more